ResearchMoz

Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market

GBI Research
Published Date » 2011-12-01
No. Of Pages » 172

GBI Research, the leading business intelligence provider, has released its latest research Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market which provides insights about monoclonal antibodies sales forecasts until 2017. Monoclonal antibodies markets in the key geographies of the US, Europe and the Rest of The World are also covered in the report. The report also includes details about monoclonal antibodies R&D pipelines and potential future blockbuster products. 

The report provides in-depth analysis of therapeutic indication, which includes HER2 Breast Cancer, Bone Metastases and Bone Loss Due to Cancer Therapy, Relapsing-remitting Multiple Sclerosis (RRMS), Metastatic Non-Small Cell Lung Cancer (NSCLC) and Rheumatoid Arthritis. Furthermore, it includes market forecasts for each of the covered therapeutic indications. The report also explores the competitive landscape with a competitive analysis of the top companies in the market. 

GBI Research analysis estimated the global monoclonal antibodies market to be valued at $15.6 billion in 2010, with a compound annual growth rate (CAGR) of 36.7% between 2002 and 2010. The market is forecast to grow at a CAGR of 10.6% between 2010 and 2017 and to reach $31.7billion by 2017. In-depth analysis in the report is based on propriety databases, primary and secondary research and inhouse analysis by the GBI Research team of experts.

GBI Research analysis found the R&D pipeline for the monoclonal antibodies market to be moderate. Many of the major pharmaceutical companies such as Roche, Amgen, and Johnson & Johnson are expanding into this market. This indicates that monoclonal antibodies R&D activity will remain active for at least the next four to five years.

Scope

  • Data and analysis of the monoclonal antibodies market in the leading geographies of the world: the US and Europe. The indications treated by different classes of MAbs discussed, which are covered in this report are in breast cancer, bone loss & metastasis, RRMS, NSCLC and rheumatoid arthritis.
  • Annualized market data for the monoclonal antibodies market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
  • Key drivers and restraints that have had significant impact on the market.
  • Competitive landscape of the global monoclonal antibodies market including benchmarking of the top companies. The key companies analysed in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Eli Lilly

Reasons to buy

  • Build effective strategies to launch pipeline products, by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of the top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety.
Table of Contents

1 Table of Contents

1 Table of Contents 3
1.1 List of Tables 8
1.2 List of Figures 12

2 Monoclonal Antibodies Market to 2017 - Introduction 15
2.1 GBI Research Report Guidance 16

3 Monoclonal Antibodies Market to 2017 - Market Characterization 17
3.1 Introduction 17
3.1.1 Stability in the Body 17
3.1.2 Systemic Cancer Treatment 17
3.1.3 Targeted Therapy 17
3.2 Monoclonal Antibody Technology 18
3.2.1 Hybridoma Technology 18
3.2.2 FuCell Technology 18
3.3 Revenue Forecasts Global 19
3.3.1 Prescription Population 19
3.3.2 Annual Cost of Therapy 20
3.3.3 Revenue 22
3.4 Revenue Forecasts Countrywise 23
3.4.1 US 23
3.4.2 Europe 24
3.4.3 Rest of the World (ROW) 25
3.5 Treatment Usage Patterns 26
3.5.1 The US 26
3.5.2 Europe 28
3.5.3 ROW 29
3.6 Annual Cost of Therapy 30
3.6.1 The US 30
3.6.2 Europe 31
3.6.3 ROW 32
3.7 Global MAbs Trends 33
3.7.1 Market Trends 33
3.7.2 Technology Trends 33
3.8 Product Trends 33
3.8.1 Research and Development Focus Shifted Towards Humanized and Fully Human MAbs 33
3.9 Global MAbs Market Drivers 34
3.9.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth 34
3.9.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy 34
3.9.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs 34
3.9.4 Expanded Indications Opens up New Potential Patient Groups 34
3.9.5 Lack of Generics Augmented the Sales Growth of MAbs 35
3.10 Global MAbs Market Restraints 35
3.10.1 High Cost of MAbs Hampering the Growth of Treatment Population 35
3.10.2 Adverse Effects Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy 35
3.10.3 Industry Challenges Majority of MAbs Receive Approvals as Last Option Therapies 35
3.11 Unmet Needs 36
3.11.1 Reduction in High Cost of MAb Therapies is the Major Unmet Need and it is also Responsible for Low Utilization by Patients 36
3.11.2 MAbs Do Not Cure Diseases; They either Treat Signs and Symptoms or Decelerate Cell Proliferation 36

4 Monoclonal Antibodies Market to 2017 - Breast Cancer (Adjuvant and Metastatic) 37
4.1 Overview 37
4.2 Introduction 37
4.3 Prescription Population 40
4.3.1 Global 40
4.3.2 The US 42
4.3.3 Europe 43
4.3.4 ROW 44
4.4 Annual Cost of Therapy 45
4.4.1 Global 45
4.4.2 The US 46
4.4.3 Europe 47
4.4.4 ROW 48
4.5 Market Size 49
4.5.1 The US 50
4.5.2 Europe 52
4.5.3 ROW 53
4.6 Marketed Products 54
4.6.1 Herceptin (trastuzumab) 54
4.7 Pipeline Analysis 55
4.7.1 Phase lll 56
4.7.2 Phase ll 58
4.7.3 Phase l 61
4.7.4 Preclinical/Discovery 62
4.8 Promising Molecules 63
4.8.1 Pertuzumab (2C4, trade name Omnitarg) 63
4.8.2 Ramucirumab (IMC-1121B) 63

5 MAbs Market Size in Bone Metastases and Bone Loss Due to Cancer Therapy 64
5.1 Introduction 64
5.2 Epidemiology 65
5.3 Diagnosis 65
5.4 Treatment 65
5.5 Prescription Population 66
5.5.1 Global 66
5.5.2 The US 67
5.5.3 Europe 68
5.5.4 ROW 69
5.6 Annual Cost of Therapy 70
5.6.1 Global 70
5.6.2 The US 71
5.6.3 Europe 72
5.6.4 ROW 73
5.7 Market Size 74
5.7.1 Global 74
5.7.2 The US 75
5.7.3 Europe 76
5.7.4 ROW 77
5.8 Marketed Products 78
5.8.1 Xgeva (denosumab) 78
5.9 Pipeline Analysis 79
5.9.1 NDA Filed 79
5.9.2 Phase ll 79
5.9.3 Phase l 79
5.9.4 Preclinical/Discovery 79

6 MAbs Market Size in Relapsing-Remitting Multiple Sclerosis (RRMS) 80
6.1 Introduction 80
6.2 Epidemiology 80
6.3 Diagnosis 80
6.4 Treatment 81
6.5 Prescription Population 81
6.5.1 Global 81
6.5.2 The US 83
6.5.3 Europe 84
6.5.4 ROW 85
6.6 Annual Cost of Therapy 86
6.6.1 Global 86
6.6.2 The US 87
6.6.3 Europe 88
6.6.4 ROW 89
6.7 Market Size 90
6.7.1 Global 90
6.7.2 The US 91
6.7.3 Europe 92
6.7.4 ROW 93
6.8 Marketed Products 94
6.8.1 Description 94
6.8.2 Mechanism of Action 94
6.8.3 Indications and Usage 94
6.8.4 Dosage 94
6.9 Pipeline Analysis 95
6.9.1 Phase lll 95
6.9.2 Phase ll 95
6.9.3 Phase l 96
6.9.4 Preclinical/Discovery 96
6.10 Promising Molecules 96
6.10.1 Campath (Alemtuzumab) 96
6.10.2 Ocrelizumab 97

7 MAbs Market Size in Metastatic Non-Small Cell Lung Cancer (NSCLC) 98
7.1 Introduction 98
7.2 Epidemiology 98
7.3 Diagnosis 98
7.4 Prescription Population 100
7.4.1 Global 100
7.4.2 The US 101
7.4.3 Europe 102
7.4.4 ROW 103
7.5 Annual Cost of Therapy 104
7.5.1 Global 104
7.5.2 The US 105
7.5.3 Europe 106
7.5.4 ROW 107
7.6 Market Size 108
7.6.1 Global 108
7.6.2 The US 109
7.6.3 Europe 110
7.6.4 ROW 111
7.7 Marketed Products 112
7.7.1 Avastin 112
7.8 Pipeline Analysis 112
7.8.1 Phase III 113
7.8.2 Phase II 114
7.8.3 Phase I 119
7.9 Promising Molecule 120
7.9.1 Necitimumab 120
7.9.2 Ramucirumab 121

8 Monoclonal Antibodies Market to 2017 - Rheumatoid Arthritis 122
8.1 Introduction 122
8.2 Epidemiology 122
8.3 Diagnosis 122
8.4 Treatment 123
8.5 Prescription Population 124
8.5.1 Global 124
8.5.2 The US 125
8.5.3 Europe 126
8.5.4 ROW 127
8.6 Annual Cost of Therapy 128
8.6.1 Global 128
8.6.2 The US 129
8.6.3 Europe 130
8.6.4 ROW 131
8.7 Market Size 132
8.7.1 Global 132
8.7.2 The US 133
8.7.3 Europe 134
8.7.4 ROW 135
8.8 Marketed Products 136
8.8.1 Rituxan 136
8.8.2 Remicade 136
8.8.3 Humira 136
8.8.4 Cimzia 136
8.8.5 Simponi 137
8.8.6 Actemra 137
8.9 Pipeline Analysis 138
8.9.1 Phase III 138
8.9.2 Phase II 139
8.9.3 Phase I 140
8.9.4 Preclinical/ Discovery Phase 140
8.10 Promising Molecule 141
8.10.1 Ofatumumab (Arzerra) 141
8.10.2 SAR153191(REGN88) 141

9 Monoclonal Antibodies Market to 2017 - Competitive Landscape 143
9.1 Market Share Analysis 143
9.1.1 Major Companies 143
9.2 Amgen Inc 143
9.3 Abbott Laboratories 145
9.4 Johnson & Johnson 146
9.5 Novartis AG 147
9.6 Biogen Idec 148
9.7 Merck & Co Inc 149
9.7.1 Company Profile 149
9.7.2 Marketed Products 149
9.7.3 SWOT Analysis 149
9.8 Eli Lilly and Company 150
9.8.1 Company Profile 150
9.8.2 Marketed Products 150
9.8.3 SWOT Analysis 150
9.9 Roche 151
9.9.1 Company Profile 151
9.9.2 Marketed Products 151
9.9.3 SWOT Analysis 151

10 Monoclonal Antibodies Market to 2017 - Strategic Consolidations 152
10.1 Deal Type 152
10.2 Mergers & Acquisitions 152
10.2.1 By Geography 152
10.2.2 M&A by Year 153
10.2.3 M&A by Value 154
10.2.4 Top M&A Deals 155
10.3 Licensing Agreement 157
10.3.1 By Geography 157
10.3.2 By Year 157
10.3.3 By Value 158
10.3.4 Licensing Agreement Deals by Value 158
10.3.5 Top Five Licensing Deals 161
10.4 Partnerships 163
10.4.1 By Geography 163
10.4.2 By Year 163
10.4.3 By Value 164

11 Monoclonal Antibodies Market to 2017 - Appendix 167
11.1 Market Definitions 167
11.2 Abbreviations 167
11.3 Research Methodology 167
11.3.1 Coverage 167
11.3.2 Secondary Research 168
11.3.3 Primary Research 168
11.3.4 Therapeutic Landscape 169
11.3.5 Geographical Landscape 171
11.3.6 Pipeline Analysis 171
11.3.7 Competitive Landscape 171
11.3.8 Expert Panel Validation 171
11.4 Contact Us 171
11.5 Disclaimer 172
11.6 Sources 172

List of Tables


Table 1: Monoclonal Antibodies Market, Global, Prescription Population (thousands), 2002-2010 19
Table 2: Monoclonal Antibodies Market, Global, Prescription Population, 2010-2017 19
Table 3: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2002-2010 20
Table 4: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2010-2017 21
Table 5: Monoclonal Antibodies Market, Global, Revenue ($bn), 2002-2010 22
Table 6: Monoclonal Antibodies Market, Global, Revenue Forecasts ($bn), 2010-2017 22
Table 7: Monoclonal Antibodies Market, Global, The US, Revenue ($bn), 2002-2010 23
Table 8: Monoclonal Antibodies Market, Global, The US, Revenue Forecasts ($bn), 2010-2017 23
Table 9: Monoclonal Antibodies Market, Global, Europe, Revenue ($bn), 2002-2010 24
Table 10: Monoclonal Antibodies Market, Global, Europe, Revenue Forecasts ($bn), 2010-2017 24
Table 11: Monoclonal Antibodies Market, Global, ROW, Revenue ($bn), 2002-2010 25
Table 12: Monoclonal Antibodies Market, Global, ROW, Revenue Forecasts ($bn), 2010-2017 25
Table 13: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2002- 2010 26
Table 14: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2010- 2017 26
Table 15: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2002- 2010 28
Table 16: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2010- 2017 28
Table 17: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2002- 2010 29
Table 18: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2010- 2017 29
Table 19: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2002- 2010 30
Table 20: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2010- 2017 30
Table 21: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2002- 2010 31
Table 22: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2010- 2017 31
Table 23: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2002- 2010 32
Table 24: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2010- 2017 32
Table 25: Monoclonal Antibodies Market, Breast Cancer, Global, Prescription Population, 2002- 2010 40
Table 26: Monoclonal Antibodies Market, Breast Cancer, Global, Prescription Population, 2010- 2017 40
Table 27: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2002- 2010 42
Table 28: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2010- 2017 42
Table 29: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2002- 2010 43
Table 30: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2010- 2017 43
Table 31: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2002- 2010 44
Table 32: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2010- 2017 44
Table 33: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2002- 2010 45
Table 34: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2010- 2017 45
Table 35: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2002- 2010 46
Table 36: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2010- 2017 46
Table 37: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2002- 2010 47
Table 38: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2010- 2017 47
Table 39: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2002- 2010 48
Table 40: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2010- 2017 48
Table 41: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue ($bn), 2002- 2010 49
Table 42: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue Forecasts ($bn), 2010- 2017 49
Table 43: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue ($bn), 2002- 2010 50
Table 44: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue Forecasts ($bn), 2010- 2017 50
Table 45: Monoclonal Antibodies Market, Breast Cancer, Europe, Revenue ($bn), 2002- 2010 52
Table 46: Monoclonal Antibodies Market, Breast Cancer, Europe, Revenue Forecasts ($bn), 2010- 2017 52
Table 47: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue ($bn), 2002- 2010 53
Table 48: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue Forecasts ($bn), 2010- 2017 53
Table 49: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase lll Molecules, 2011 56
Table 50: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase ll Molecules, 2011 58
Table 51: Monoclonal Antibodies Market, HER2 Breast Cancer, Phase l Molecules, 2011 61
Table 52: Monoclonal Antibodies Market, HER2 Breast Cancer, Preclinical/Discovery Molecules, 2011 62
Table 53: Monoclonal Antibodies Market, Bone Metastasis, Global, Prescription Population, 2011- 2017 66
Table 54: Monoclonal Antibodies Market, Bone Metastasis, the US, Prescription Population, 2011- 2017 67
Table 55: Monoclonal Antibodies Market, Bone Metastasis, Europe, Prescription Population, 2011- 2017 68
Table 56: Monoclonal Antibodies Market, Bone Metastasis, ROW, Prescription Population, 2011- 2017 69
Table 57: Monoclonal Antibodies Market, Bone Metastasis, Global, Annual Cost of Therapy ($), 2011- 2017 70
Table 58: Monoclonal Antibodies Market, Bone Metastasis,The US, Annual Cost of Therapy ($), 2011- 2017 71
Table 59: Monoclonal Antibodies Market, Bone Metastasis,Europe, Annual Cost of Therapy, 2011- 2017 72
Table 60: Monoclonal Antibodies Market, Bone Metastasis, ROW, Annual Cost of Therapy ($), 2011- 2017 73
Table 61: Monoclonal Antibodies Market, Bone Metastasis, Global, Revenue Forecasts ($bn), 2011- 2017 74
Table 62: Monoclonal Antibodies Market, Bone Metastasis,The US, Revenue Forecasts ($m), 2011- 2017 75
Table 63: Monoclonal Antibodies Market, Bone Metastasis, Europe, Revenue Forecasts ($m), 2011- 2017 76
Table 64: Monoclonal Antibodies Market, Bone Metastasis, ROW, Revenue Forecasts ($m), 2011- 2017 77
Table 65: Monoclonal Antibodies Market, Bone Metastasis, NDA Filed Molecules , 2011 79
Table 66: Monoclonal Antibodies Market, Bone Metastasis, Phase ll Molecules , 2011 79
Table 67: Monoclonal Antibodies Market, Bone Metastasis, Phase l Molecules , 2011 79
Table 68: Monoclonal Antibodies Market, Bone Metastasis, Preclinical/Discovery Molecules , 2011 79
Table 69: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2006- 2010 81
Table 70: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2010- 2017 82
Table 71: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2006- 2010 83
Table 72: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2010- 2017 83
Table 73: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2006- 2010 84
Table 74: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2010- 2017 84
Table 75: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2009- 2010 85
Table 76: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2010- 2017 85
Table 77: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2006- 2010 86
Table 78: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2010- 2017 86
Table 79: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2006- 2010 87
Table 80: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2010- 2017 87
Table 81: Monoclonal Antibodies Market, RRMS,Europe, Annual Cost of Therapy ($), 2006 2010 88
Table 82: Monoclonal Antibodies Market, RRMS,Europe, Annual Cost of Therapy ($), 2010- 2017 88
Table 83: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2006- 2010 89
Table 84: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2010- 2017 89
Table 85: Monoclonal Antibodies Market, RRMS, Global, Revenue ($bn), 2006- 2010 90
Table 86: Monoclonal Antibodies Market, RRMS, Global, Revenue Forecasts ($bn), 2010- 2017 90
Table 87: Monoclonal Antibodies Market, RRMS,The US, Revenue ($m), 2006- 2010 91
Table 88: Monoclonal Antibodies Market, RRMS,The US, Revenue Forecasts ($m), 2010- 2017 91
Table 89: Monoclonal Antibodies Market, RRMS,Europe, Revenue ($m), 2006- 2010 92
Table 90: Monoclonal Antibodies Market, RRMS,Europe, Revenue Forecasts ($m), 2010- 2017 92
Table 91: Monoclonal Antibodies Market, RRMS, ROW, Revenue ($m), 2009- 2010 93
Table 92: Monoclonal Antibodies Market, RRMS, ROW, Revenue Forecasts ($m), 2010- 2017 93
Table 93: Monoclonal Antibodies Market, RRMS, Phase lll Molecules, 2011 95
Table 94: Monoclonal Antibodies Market, RRMS, Phase ll Molecules, 2011 95
Table 95: Monoclonal Antibodies Market, RRMS, Phase l Molecules, 2011 96
Table 96: Monoclonal Antibodies Market, RRMS, Preclinical/Discovery Molecules, 2011 96
Table 97: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2007- 2010 100
Table 98: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2010- 2017 100
Table 99: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2007- 2010 101
Table 100: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2010- 2017 101
Table 101: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2008- 2010 102
Table 102: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2010- 2017 102
Table 103: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2007- 2010 103
Table 104: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2010- 2017 103
Table 105: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2007- 2010 104
Table 106: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2010- 2017 104
Table 107: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2007- 2010 105
Table 108: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2010- 2017 105
Table 109: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2008- 2010 106
Table 110: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2010- 2017 106
Table 111: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2007- 2010 107
Table 112: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2010- 2017 107
Table 113: Monoclonal Antibodies Market, NSCLC, Global, Revenue ($bn), 2007- 2010 108
Table 114: Monoclonal Antibodies Market, NSCLC, Global, Revenue Forecasts ($bn), 2010- 2017 108
Table 115: Monoclonal Antibodies Market, NSCLC, The US, Revenue ($bn), 2007- 2010 109
Table 116: Monoclonal Antibodies Market, NSCLC, The US, Revenue Forecasts ($bn), 2010- 2017 109
Table 117: Monoclonal Antibodies Market, NSCLC, Europe, Revenue ($million), 2008- 2010 110
Table 118: Monoclonal Antibodies Market, NSCLC, Europe, Revenue Forecasts ($million), 2010- 2017 110
Table 119: Monoclonal Antibodies Market, NSCLC, ROW, Revenue ($m), 2007- 2010 111
Table 120: Monoclonal Antibodies Market, NSCLC, ROW, Revenue Forecasts ($m), 2010- 2017 111
Table 121: Monoclonal Antibodies Market, NSCLC, Phase lll Molecules, 2011 113
Table 122: Monoclonal Antibodies Market, NSCLC, Phase ll Molecules, 2011 114
Table 123: Monoclonal Antibodies Market, NSCLC, Phase l Molecules, 2011 119
Table 124: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2002- 2010 124
Table 125: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2010- 2017 124
Table 126: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2002- 2010 125
Table 127: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2010- 2017 125
Table 128: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2002- 2010 126
Table 129: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2010- 2017 126
Table 130: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2002- 2010 127
Table 131: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2010- 2017 127
Table 132: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2002- 2010 128
Table 133: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2010- 2017 128
Table 134: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2002- 2010 129
Table 135: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2010- 2017 129
Table 136: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2002- 2010 130
Table 137: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2010- 2017 130
Table 138: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2002- 2010 131
Table 139: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2010- 2017 131
Table 140: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue ($bn), 2002- 2010 132
Table 141: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue Forecasts ($bn), 2010- 2017 132
Table 142: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue ($bn), 2002- 2010 133
Table 143: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue Forecasts ($bn), 2010- 2017 133
Table 144: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue ($m), 2002- 2010 134
Table 145: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue ($m), 2002- 2010 134
Table 146: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue ($bn), 2002- 2010 135
Table 147: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue Forecasts ($bn), 2010- 2017 135
Table 148: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase III Molecules, 2011 138
Table 149: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase II Molecules, 2011 139
Table 150: Monoclonal Antibodies Market, Rheumatoid Arthritis, Phase I Molecules, 2011 140
Table 151: Monoclonal Antibodies Market, Rheumatoid Arthritis, Preclinical/ Discovery Phase Molecules, 2011 140
Table 152: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010 144
Table 153: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010 145
Table 154: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010 146
Table 155: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010 148
Table 156: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010 149
Table 157: Monoclonal Antibodies Market to 2017, Marketed Products, Sales ($m), 2010 151
Table 158: Monoclonal Antibodies Market, Strategic Consolidations, Top M&A Deals, 2011 155
Table 159: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement Deals by Value, 2011 158
Table 160: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Value, 2011 164

List of Figures


Figure 1: Monoclonal Antibodies Market, Global, Drivers and Barriers, 2011 17
Figure 2: Monoclonal Antibodies Market, Global, Prescription Population (thousands), 2002-2017 19
Figure 3: Monoclonal Antibodies Market, Global, Annual Cost of Therapy ($), 2002-2017 20
Figure 4: Monoclonal Antibodies Market, Global, Revenue Forecasts ($bn), 2002-2017 22
Figure 5: Monoclonal Antibodies Market, Global, The US, Revenue Forecasts ($bn), 2002-2017 23
Figure 6: Monoclonal Antibodies Market, Global, Europe, Revenue Forecasts ($bn), 2002-2017 24
Figure 7: Monoclonal Antibodies Market, Global, ROW, Revenue Forecasts ($bn), 2002-2017 25
Figure 8: Monoclonal Antibodies Market, Global,The US, Prescription Population, 2002- 2017 26
Figure 9: Monoclonal Antibodies Market, Global,Europe, Prescription Population, 2002- 2017 28
Figure 10: Monoclonal Antibodies Market, Global, ROW, Prescription Population, 2002- 2017 29
Figure 11: Monoclonal Antibodies Market, Global, The US, Annual Cost of Therapy ($), 2002- 2017 30
Figure 12: Monoclonal Antibodies Market, Global, Europe, Annual Cost of Therapy ($), 2002- 2017 31
Figure 13: Monoclonal Antibodies Market, Global, ROW, Annual Cost of Therapy ($), 2002- 2017 32
Figure 14: Monoclonal Antibodies Market, Global, Revenue Distibution by Indication (%), 2011 37
Figure 15: Monoclonal Antibodies Market, Breast Cancer,Global, Prescription Population, 2002- 2017 40
Figure 16: Monoclonal Antibodies Market, Breast Cancer, the US, Prescription Population, 2002- 2017 42
Figure 17: Monoclonal Antibodies Market, Breast Cancer,Europe, Prescription Population, 2002- 2017 43
Figure 18: Monoclonal Antibodies Market, Breast Cancer, ROW, Prescription Population, 2002- 2017 44
Figure 19: Monoclonal Antibodies Market, Breast Cancer, Global, Annual Cost of Therapy ($), 2002- 2017 45
Figure 20: Monoclonal Antibodies Market, Breast Cancer,The US, Annual Cost of Therapy ($), 2002- 2017 46
Figure 21: Monoclonal Antibodies Market, Breast Cancer, Europe, Annual Cost of Therapy ($), 2002- 2017 47
Figure 22: Monoclonal Antibodies Market, Breast Cancer, ROW, Annual Cost of Therapy ($), 2002- 2017 48
Figure 23: Monoclonal Antibodies Market, Breast Cancer, Global, Revenue Forecasts ($bn), 2002- 2017 49
Figure 24: Monoclonal Antibodies Market, Breast Cancer,The US, Revenue Forecasts ($bn), 2002- 2017 50
Figure 25: Monoclonal Antibodies Market, Breast Cancer,Europe, Revenue Forecasts ($bn), 2002- 2017 52
Figure 26: Monoclonal Antibodies Market, Breast Cancer, ROW, Revenue Forecasts ($bn), 2002- 2017 53
Figure 27: Monoclonal Antibodies Market, HER2 Breast Cancer, Pipeline Analysis (%), 2011 55
Figure 28: Monoclonal Antibodies Market, Bone Metastasis, Global, Prescription Population, 2011- 2017 66
Figure 29: Monoclonal Antibodies Market, Bone Metastasis, the US, Prescription Population, 2011- 2017 67
Figure 30: Monoclonal Antibodies Market, Bone Metastasis, Europe, Prescription Population, 2011- 2017 68
Figure 31: Monoclonal Antibodies Market, Bone Metastasis, ROW, Prescription Population, 2011- 2017 69
Figure 32: Monoclonal Antibodies Market, Bone Metastasis, Global, Annual Cost of Therapy ($), 2011- 2017 70
Figure 33: Monoclonal Antibodies Market, Bone Metastasis,The US, Annual Cost of Therapy ($), 2011- 2017 71
Figure 34: Monoclonal Antibodies Market, Bone Metastasis,Europe, Annual Cost of Therapy, 2011- 2017 72
Figure 35: Monoclonal Antibodies Market, Bone Metastasis, ROW, Annual Cost of Therapy ($), 2011- 2017 73
Figure 36: Monoclonal Antibodies Market, Bone Metastasis, Global, Revenue Forecasts ($bn), 2011- 2017 74
Figure 37: Monoclonal Antibodies Market, Bone Metastasis,The US, Revenue Forecasts ($m), 2011- 2017 75
Figure 38: Monoclonal Antibodies Market, Bone Metastasis,Europe, Revenue Forecasts ($m), 2011- 2017 76
Figure 39: Monoclonal Antibodies Market, Bone Metastasis, ROW, Revenue Forecasts ($m), 2011- 2017 77
Figure 40: Monoclonal Antibodies Market, RRMS, Global, Prescription Population, 2006- 2017 81
Figure 41: Monoclonal Antibodies Market, RRMS,The US, Prescription Population, 2006- 2017 83
Figure 42: Monoclonal Antibodies Market, RRMS,Europe, Prescription Population, 2006- 2017 84
Figure 43: Monoclonal Antibodies Market, RRMS, ROW, Prescription Population, 2009- 2017 85
Figure 44: Monoclonal Antibodies Market, RRMS, Global, Annual Cost of Therapy ($), 2006- 2017 86
Figure 45: Monoclonal Antibodies Market, RRMS,The US, Annual Cost of Therapy ($), 2006- 2017 87
Figure 46: Monoclonal Antibodies Market, RRMS, Europe, Annual Cost of Therapy ($), 2006- 2017 88
Figure 47: Monoclonal Antibodies Market, RRMS, ROW, Annual Cost of Therapy ($), 2006- 2017 89
Figure 48: Monoclonal Antibodies Market, RRMS, Global, Revenue Forecasts ($bn), 2006- 2017 90
Figure 49: Monoclonal Antibodies Market, RRMS,The US, Revenue Forecasts ($m), 2006- 2017 91
Figure 50: Monoclonal Antibodies Market, RRMS,Europe, Revenue Forecasts ($m), 2006- 2017 92
Figure 51: Monoclonal Antibodies Market, RRMS, ROW, Revenue Forecasts ($m), 2009- 2017 93
Figure 52: Monoclonal Antibodies Market, RRMS, Pipeline Analysis, (%), 2011 95
Figure 53: Monoclonal Antibodies Market, NSCLC, Global, Prescription Population, 2007- 2017 100
Figure 54: Monoclonal Antibodies Market, NSCLC, The US, Prescription Population, 2007- 2017 101
Figure 55: Monoclonal Antibodies Market, NSCLC, Europe, Prescription Population, 2008- 2017 102
Figure 56: Monoclonal Antibodies Market, NSCLC, ROW, Prescription Population, 2007 2017 103
Figure 57: Monoclonal Antibodies Market, NSCLC, Global, Annual Cost of Therapy ($), 2007- 2017 104
Figure 58: Monoclonal Antibodies Market, NSCLC, The US, Annual Cost of Therapy ($), 2007- 2017 105
Figure 59: Monoclonal Antibodies Market, NSCLC, Europe, Annual Cost of Therapy ($), 2008- 2017 106
Figure 60: Monoclonal Antibodies Market, NSCLC, ROW, Annual Cost of Therapy ($), 2007- 2017 107
Figure 61: Monoclonal Antibodies Market, NSCLC, Global, Revenue Forecasts ($bn), 2007- 2017 108
Figure 62: Monoclonal Antibodies Market, NSCLC, The US, Revenue Forecasts ($bn), 2007- 2017 109
Figure 63: Monoclonal Antibodies Market, NSCLC, Europe, Revenue Forecasts ($million), 2008- 2017 110
Figure 64: Monoclonal Antibodies Market, NSCLC, ROW, Revenue Forecasts ($m), 2007- 2017 111
Figure 65: Monoclonal Antibodies Market, NSCLC, Pipeline Analysis, (%), 2011 112
Figure 66: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Prescription Population, 2002- 2017 124
Figure 67: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Prescription Population, 2002- 2017 125
Figure 68: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Prescription Population, 2002- 2017 126
Figure 69: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Prescription Population, 2002- 2017 127
Figure 70: Monoclonal Antibodies Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2002- 2017 128
Figure 71: Monoclonal Antibodies Market, Rheumatoid Arthritis, The US, Annual Cost of Therapy ($), 2002- 2017 129
Figure 72: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Annual Cost of Therapy ($), 2002- 2017 130
Figure 73: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Annual Cost of Therapy ($), 2002- 2017 131
Figure 74: Monoclonal Antibodies Market, Rheumatoid Arthritis,Global, Revenue Forecasts ($bn), 2002- 2017 132
Figure 75: Monoclonal Antibodies Market, Rheumatoid Arthritis,The US, Revenue Forecasts ($bn), 2002- 2017 133
Figure 76: Monoclonal Antibodies Market, Rheumatoid Arthritis, Europe, Revenue Forecasts ($bn), 2002- 2017 134
Figure 77: Monoclonal Antibodies Market, Rheumatoid Arthritis, ROW, Revenue Forecasts ($bn), 2002- 2017 135
Figure 78: Monoclonal Antibodies Market, Rheumatoid Arthritis, Pipeline Analysis, (%), 2011 138
Figure 79: Monoclonal Antibodies Market to 2017, Global, Market share Analysis by Company (%), 2010 143
Figure 80: Monoclonal Antibodies Market to 2017, Amgen Inc SWOT Analysis, 2011 144
Figure 81: Monoclonal Antibodies Market to 2017, Abbott Laboratories SWOT Analysis, 2011 145
Figure 82: Monoclonal Antibodies Market to 2017, Johnson & Johnson SWOT Analysis, 2011 146
Figure 83: Monoclonal Antibodies Market to 2017, Novartis AG SWOT Analysis, 2011 147
Figure 84: Monoclonal Antibodies Market to 2017, Biogen Idec SWOT Analysis, 2011 148
Figure 85: Monoclonal Antibodies Market to 2017, Merck & Co Inc SWOT Analysis, 2011 149
Figure 86: Monoclonal Antibodies Market to 2017, Eli Lilly and Company SWOT Analysis, 2011 150
Figure 87: Monoclonal Antibodies Market to 2017, Roche SWOT Analysis, 2011 151
Figure 88: Monoclonal Antibodies Market, Strategic Consolidations, Analysis by Deal Type, 2010-2011 152
Figure 89: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Geography, 2011 152
Figure 90: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Year, 2011 153
Figure 91: Monoclonal Antibodies Market, Strategic Consolidations, M&A, Analysis by Value, 2011 154
Figure 92: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Geography, 2011 157
Figure 93: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Year, 2011 157
Figure 94: Monoclonal Antibodies Market, Strategic Consolidations, Licensing Agreement, Analysis by Value, 2011 158
Figure 95: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Geography, 2011 163
Figure 96: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Year, 2011 163
Figure 97: Monoclonal Antibodies Market, Strategic Consolidations, Partnerships, Analysis by Value, 2011 164
Figure 98: GBI Research Market Forecasting Model 170

Upcoming Reports:

Fiber Optic Connectors Market - Global Industry Analysis, Market Size, Market Share, Growth and Forecast, 2013 - 2019
By - Transparency Market Research
An optical fiber connector is used to terminate the end of an optical fiber cable and it enables quicker connection. The connectors couple and align the core if fiber cable mechanically so that light can pass through it. These connectors are used to join optical fibers where a disconnect or connect capability is mandatory. The basis unit is a connector assembly. Most of the optical fiber connectors are spring-loaded, so when the fiber faces are pressed together when the connectors are mated. The resulting plastic to plastic and glass to glass contact eliminates signal losses that would be...
Poland: propylene market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the propylene market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the propylene market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Drug & Alcohol Screening Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2013 - 2019
By - Transparency Market Research
Drug and alcohol screening tests focuses on providing vital protection of public and employee safety. Drug and alcohol screening testsreducesthe risk of human injury and property damage as well as help organizations to establish a strong and safe culture. Now-a-days various organizations are increasingly opting for employee drug and alcohol screening for prevention of occupational hazards atthe workplace; that may occur due to the use of recreational drugs and alcohol. Drug and alcohol screening is also helpful in pre-employment assessment. The use of illicit drugs amongst a workforce can...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...